Literature DB >> 15611260

Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.

Florian Klein1, Niklas Feldhahn, Jana L Mooster, Mieke Sprangers, Wolf-Karsten Hofmann, Peter Wernet, Maria Wartenberg, Markus Müschen.   

Abstract

The BCR-ABL1 kinase expressed in acute lymphoblastic leukemia (ALL) drives malignant transformation of pre-B cells and prevents further development. We studied whether inhibition of BCR-ABL1 kinase activity using STI571 can relieve this differentiation block. STI571 treatment of leukemia patients induced expression of the Ig L chain-associated transcription factors IRF4 and SPIB, up-regulation of RAG1 and RAG2, Ckappa and Clambda germline transcription, and rearrangement of Ig kappa L chain (IGK) and Ig lambda L chain (IGL) genes. However, STI571-treated pre-B ALL cells expressed lambda L, but almost no kappa L chains. This could be explained by STI571-induced rearrangement of the kappa-deleting element (KDE), which can delete productively rearranged Vkappa-Jkappa joints. Amplifying double-strand breaks at recombination signal sequences within the IGK, KDE, and IGL loci revealed a coordinated sequence of rearrangement events induced by STI571: recombination of IGK gene segments was already initiated within 1 h after STI571 treatment, followed by KDE-mediated deletion of Vkappa-Jkappa joints 6 h later and, ultimately, IGL gene rearrangement after 12 h. Consistently, up-regulation of Ckappa and Clambda germline transcripts, indicating opening of IGK and IGL loci, was detected after 1 and 6 h for IGK and IGL, respectively. Continued activity of the recombination machinery induced secondary IGK gene rearrangements, which shifted preferential usage of upstream located Jkappa- to downstream Jkappa-gene segments. Thus, inhibition of BCR-ABL1 in pre-B ALL cells 1) recapitulates early B cell development, 2) directly shows that IGK, KDE, and IGL genes are rearranged in sequential order, and 3) provides a model for Ig L chain gene regulation in the human.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15611260     DOI: 10.4049/jimmunol.174.1.367

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.

Authors:  Katarina Ochodnicka-Mackovicova; Mahnoush Bahjat; Timon A Bloedjes; Chiel Maas; Alexander M de Bruin; Richard J Bende; Carel J M van Noesel; Jeroen E J Guikema
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

2.  Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.

Authors:  Niklas Feldhahn; Paula Río; Bonaventure Ndikung Bejeng Soh; Stefanie Liedtke; Mieke Sprangers; Florian Klein; Peter Wernet; Hassan Jumaa; Wolf-Karsten Hofmann; Helmut Hanenberg; Janet D Rowley; Markus Müschen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

3.  IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner.

Authors:  Seung-Hee Jo; Ruibao Ren
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

4.  Diverse immunoglobulin light chain organizations in fish retain potential to revise B cell receptor specificities.

Authors:  Ellen Hsu; Michael F Criscitiello
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

5.  Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.

Authors:  Seung-Hee Jo; Jonathan H Schatz; Jaime Acquaviva; Harinder Singh; Ruibao Ren
Journal:  Blood       Date:  2010-06-28       Impact factor: 22.113

6.  Accumulation of B1-like B cells in transgenic mice over-expressing catalytically inactive RAG1 in the periphery.

Authors:  Ashraf E Hassaballa; Victoria L Palmer; Dirk K Anderson; Michele D Kassmeier; Vincent K Nganga; Kevin W Parks; Dustin L Volkmer; Greg A Perry; Patrick C Swanson
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

7.  Pre-B cell receptor signaling in acute lymphoblastic leukemia.

Authors:  Rahul Nahar; Markus Müschen
Journal:  Cell Cycle       Date:  2009-12-09       Impact factor: 4.534

8.  BCL6 is critical for the development of a diverse primary B cell repertoire.

Authors:  Cihangir Duy; J Jessica Yu; Rahul Nahar; Srividya Swaminathan; Soo-Mi Kweon; Jose M Polo; Ester Valls; Lars Klemm; Seyedmehdi Shojaee; Leandro Cerchietti; Wolfgang Schuh; Hans-Martin Jäck; Christian Hurtz; Parham Ramezani-Rad; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; Ignacio Moreno de Alborán; Ari M Melnick; B Hilda Ye; Markus Müschen
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

9.  Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.

Authors:  Alex Yick-Lun So; Reeshelle Sookram; Aadel A Chaudhuri; Aarathi Minisandram; David Cheng; Catherine Xie; Ee Lyn Lim; Yvette Garcia Flores; Shuai Jiang; Jocelyn Tammy Kim; Christopher Keown; Parameswaran Ramakrishnan; David Baltimore
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

10.  IRF-4 functions as a tumor suppressor in early B-cell development.

Authors:  Jaime Acquaviva; Xiaoren Chen; Ruibao Ren
Journal:  Blood       Date:  2008-08-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.